CA
JANX icon

Crewe Advisors’s Janux Therapeutics JANX Stock Holding History

Crewe Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-115
Closed -$1.39K – 954
2023
Q1 		$1.39K Hold
115
– – ﹤0.01% 739
2022
Q4 		$1.51K Hold
115
– – ﹤0.01% 875
2022
Q3 		$2K Hold
115
– – ﹤0.01% 1049
2022
Q2 		$1K Buy
+115
New +$1.36K ﹤0.01% 1078

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Crewe Advisors's JANX Position: Q2 2023 in Review

Crewe Advisors sold out of Janux Therapeutics (JANX) in Q2 2023, closing a stake of 115 shares — an estimated $1.39K sold.

Crewe Advisors first reported a position in JANX in Q2 2022 and held it in 4 quarters. The position peaked at $2K in Q3 2022. 54 funds tracked by Wall St. Rank hold JANX as of Q2 2023.

  • Crewe Advisors reported no remaining Janux Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 115 Janux Therapeutics shares in Q2 2023, an estimated $1.39K.
  • Crewe Advisors first reported a position in Janux Therapeutics in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Janux Therapeutics position peaked at $2K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.